Abstract
Treatment of tumors with monoclonal antibodies against tumor antigen is one of the selective modalities for cancer therapy. We examined the therapeutic effect of MRK‐20 (IgG1), a murine monoclonal antibody against resistance‐associated 85‐kDa membrane protein. The 85‐kDa protein is expressed on the surface of multidrug‐resistant cells induced by adriamycin. This protein is also expressed in some multiple‐drug‐resistant cells, including atypical multidrug‐resistant cells. The protein, once lost during long‐term culture without adriamycin, was rapidly induced by treatment with adriamycin but not with vinblastine or etoposide, suggesting a close relationship of the protein with adriamycin resistance but not with multidrug resistance. The antibody MRK‐20 suppressed the growth of subcutaneously implanted tumors expressing the 85‐kDa protein. Adriamycin‐resistant human ovarian tumor 2780AD and innately resistant human erythroleukemia HEL cells in athymic mice were completely cured by treatment with MRK‐20 antibody when the antibody was administered i.v. 2 days after s.c. tumor implantation. On the other hand, MRK‐20 did not show any effect on the growth of the 85‐kDa protein‐negative A2780 human ovarian tumor. These results indicate that the effect of MRK‐20 is highly specific to cells expressing 85‐kDa protein.
Keywords: Monoclonal antibody, Antitumor activity, Membrane protein (85‐kDa), Human tumor xenograft
Full Text
The Full Text of this article is available as a PDF (373.2 KB).
REFERENCES
- 1. ) Reisfeld , R. A. and Sell , S. “ Monoclonal Antibodies and Cancer Therapy ” ( 1985. ). Alan R. Liss, Inc. , New York . [Google Scholar]
- 2. ) Scheinberg , D. A. and Houghton , A. N.Current status of antitumor therapy with monoclonal antibodies . Oncology , 1 , 31 – 40 ( 1987. ). [PubMed] [Google Scholar]
- 3. ) Mellstedt , H.Monoclonal antibodies in cancer therapy . Curr. Opin. Immunol. , 2 , 708 – 713 ( 1990. ). [DOI] [PubMed] [Google Scholar]
- 4. ) Cheresh , D. A. , Harper , J. R. , Schulz , G. and Reisfeld , R. A.Localization of the gangliosides Gd2 and Gd3 in adhesion plaque and on surface of human melanoma cells . Proc. Natl. Acad. Sci. USA , 81 , 5767 – 5771 ( 1984. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. ) Hakomori , S‐I. and Kannagi , R.Glycosphingolipids as tumor‐associated and differentiation makers . J. Natl. Cancer Inst. , 71 , 231 – 251 ( 1983. ). [PubMed] [Google Scholar]
- 6. ) Cheung , N. K. , Saarinen , U. M. , Neely , J. E. , Landmeier , B. , Donovan , D. and Coccia , P. F.Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells . Cancer Res. , 45 , 2642 – 2649 ( 1985. ). [PubMed] [Google Scholar]
- 7. ) Stancovski , L. , Hurwitz , E. , Leitner , D. , Ullrich , A. , Yarden , Y. and Sela , M.Mechanistic aspects of the opposing effects of monoclonal antibodies to the erbB‐2 receptor on tumor growth . Proc. Natl. Acad. Sci. USA , 88 , 8691 – 8695 ( 1991. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. ) Dillman , R. , Shawler , D. , Dillman , J. and Roystan , R.Therapy of chronic lymphocytic leukemia and cutaneous T‐cell lymphoma with T101 monoclonal antibody . J. Clin. Oncol. , 2 , 881 – 891 ( 1984. ). [DOI] [PubMed] [Google Scholar]
- 9. ) Mansoor , N. S. , Khazaeli , M. B. , Wheeler , R. H. , Dropcho , E. , Liu , T. , Urist , M. , Miller , D. M. , Lawson , S. , Dixon , P. , Russell , C. H. and LoBuglio , A. F.Phase I trial of the murine monoclonal anti‐GD2 antibody 14G2a in metastatic melanoma . Cancer Res. , 52 , 4342 – 4347 ( 1992. ). [PubMed] [Google Scholar]
- 10. ) Tsuruo , T. , Hamada , H. , Sato , S. and Heike , Y.Inhibition of multidrug‐resistant human tumor growth in athymic mice by anti‐P‐glycoprotein monoclonal antibodies . Jpn. J. Cancer Res. , 80 , 627 – 631 ( 1989. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. ) Hamada , H. , Okochi , E. , Watanabe , M. , Oh‐Hara , T. , Sugimoto , Y. , Kawabata , H. and Tsuruo , T.Mr 85,000 membrane protein specifically expressed in adriamycin‐resistant human tumor cells . Cancer Res. , 48 , 7082 – 7087 ( 1988. ). [PubMed] [Google Scholar]
- 12. ) Sugawara , L , Kodo , H. , Ohkochi , E. , Hamada , H. , Tsuruo , T. and Mori , S.High‐level expression of MRK 16 and MRK 20 murine monoclonal antibody‐defined proteins (170,000–180,000 P‐glycoprotein and 85,000 protein) in leukemias and malignant lymphomas . Br. J. Cancer , 60 , 538 – 541 ( 1989. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. ) Ohtsu , T. , Ishida , Y. , Tobinai , K. , Minato , K. , Hamada , H. , Ohkochi , E. , Tsuruo , T. and Shimoyama , M.A novel multidrug resistance in cultured leukemia and lymphoma cells detected by a monoclonal antibody to 85‐kDa protein, MRK‐20 . Jpn. J. Cancer Res. , 80 , 1133 – 1140 ( 1989. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. ) Hamilton , T. C. , Young , R. C. and Ozols , R. F.Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches . Semin. Oncol. , 11 , 285 – 298 ( 1984. ). [PubMed] [Google Scholar]
- 15. ) Martin , P.Hell cells: a new human erythroleukemia cell line with spontaneous and induced globin expression . Science , 216 , 1233 – 1235 ( 1982. ). [DOI] [PubMed] [Google Scholar]
- 16. ) Tsuruo , T. , Iida‐Saito , H. , Kawabata , H. , Oh‐hara , T. , Hamada , H. and Utakoji , T.Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and isolated clones . Jpn. J. Cancer Res. , 77 , 682 – 692 ( 1986. ). [PubMed] [Google Scholar]
- 17. ) Ishii , S. , Naito , M. , Masuda , M. and Tsuruo , T.Expression of 85‐kDa protein of adriamycin‐resistant tumor cells during hematopoietic differentiation of THP‐1 and HEL cells . Jpn. J. Cancer Res. , 83 , 107 – 112 ( 1992. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. ) Sagawa , T. , Kodama , T. , Tominaga , A. and Okada , M.Human platelets effectively kill K‐562 cells, a chronic myelogenic leukemia cell line, in vitro . Jpn. J. Cancer Res. , 81 , 449 – 453 ( 1990. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. ) Riordan , J. R. and Ling , V.Genetic and biochemical characterization of multidrug resistance . Pharmacol. Ther. , 28 , 51 – 75 ( 1985. ). [DOI] [PubMed] [Google Scholar]
- 20. ) Tsuruo , T.Mechanisms of multidrug resistance and implications for therapy . Jpn. J. Cancer Res. , 79 , 285 – 296 ( 1988. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. ) Roninson I. B. ( ed ). “ Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells ” ( 1989. ). Plenum Publishing Corp. , New York . [Google Scholar]
- 22. ) Danks , M. K. , Yalowich , J. C. and Beck , W. T.Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM‐26) . Cancer Res. , 47 , 1297 – 1301 ( 1987. ). [PubMed] [Google Scholar]
- 23. ) Sugawara , I. , Ohkochi , E. , Hamada , H. , Tsuruo , T. and Mori , S.Cellular and tissue distribution of MRK20 murine monoclonal antibody‐defined 85‐kDa protein in adriamycin‐resistant cancer cell lines . Jpn. J. Cancer Res. , 79 , 1101 – 1110 ( 1988. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. ) Noguchi , K. , Naito , M. , Tezuka , K. , Ishii , S. , Seimiya , H. , Sugimoto , Y. , Amann , E. and Tsuruo , T.cDNA expression cloning of the 85‐kDa protein overexpressed in Adriamycin‐resistant cells . Biochem. Biophys. Res. Commun. , 192 , 88 – 95 ( 1993. ). [DOI] [PubMed] [Google Scholar]
- 25. ) Huang , M. , Bolen , J. B. , Barnwell , J. W. , Shattil , S. J. and Brugge , J. S.Membrane glycoprotein IV (CD36) is physically associated with the Fyn, Lyn, and Yes proteintyrosine kinase in human platelets . Proc. Natl. Acad. Sci. USA , 88 , 7844 – 7848 ( 1991. ). [DOI] [PMC free article] [PubMed] [Google Scholar]